Aethlon Medical's Upcoming Virtual Investor Conferences
Aethlon Medical, Inc. (NASDAQ: AEMD) is committed to developing cutting-edge therapies for cancer and serious infectious diseases, and they have some exciting news for their investors. In September, they're set to present at two important virtual investor conferences where they will discuss their latest developments and engage with the investment community.
Life Sciences Investor Forum Presentation
On September 19 and 20, Aethlon Medical's interim CEO and CFO, James Frakes, along with Dr. Steven LaRosa, the company's Chief Medical Officer, will provide an overview of the company during the Life Sciences Investor Forum. This virtual conference will allow for direct interaction between investors and the company's management team.
Details of the Life Sciences Investor Forum
The presentation is confirmed for September 19, 2024, at 1:30 pm ET. Investors interested in attending can pre-register for the event, which includes the opportunity to pose questions in real-time directly to the management team. Additionally, an archived version of the presentation will be made available afterward for those who wish to revisit the conversation.
Insights from the Virtual Emerging Growth Conference
Following the Life Sciences Investor Forum, Aethlon Medical will also participate in the Virtual Emerging Growth Conference on September 25, 2024. The same leadership team will again reveal essential insights into the company's strategic directions and advancements in their medical therapies.
Presentation Insights for the Emerging Growth Conference
This particular presentation is scheduled to take place on September 25, 2024, at 12:35 pm ET. After the session, there will be an opportunity for questions, enabling investors to further engage with the leadership of Aethlon Medical. Investors can send in questions beforehand, leading to a lively and interactive Q&A segment during the conference.
Aethlon Medical and Their Innovations
Aethlon Medical is at the forefront of developing the Hemopurifier, a vital medical device aimed at addressing both cancer and life-threatening viral infections. This innovative device has been through several studies, showing its ability to remove harmful viruses and exosomes from biological fluids, utilizing a one-of-a-kind lectin-based technology.
The Impact of the Hemopurifier
The Hemopurifier has been designated as a Breakthrough Device by the U.S. FDA, highlighting its significant potential in treating advanced or metastatic cancers, particularly in cases where patients have not responded to traditional treatments. Furthermore, this device also has an open Investigational Device Exemption (IDE) application for addressing dangerous viruses that currently lack approved treatment options.
Company Insights and Future Directions
Aethlon Medical is dedicated to meeting the unmet medical needs in the fields of cancer and infectious diseases. The upcoming presentations will offer valuable insights into their strategic initiatives, aimed at positioning the company advantageously within a competitive landscape. Investors are encouraged to engage with the leadership team during these two virtual conferences to gain a deeper understanding of Aethlon's evolving role in healthcare innovation.
Contact Information for Inquiries
For further questions or information, investors can reach out to:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
Frequently Asked Questions
What will Aethlon Medical present at the conferences?
Aethlon Medical will discuss company overviews and new innovations, particularly focusing on their Hemopurifier technology.
When are the scheduled presentations?
The presentation at the Life Sciences Investor Forum is on September 19, and the session for the Virtual Emerging Growth Conference is on September 25, both occurring in 2024.
Who is presenting for Aethlon Medical?
James Frakes, the Interim CEO and CFO, along with Dr. Steven LaRosa, the Chief Medical Officer, will be presenting at both events.
How can investors interact with the company during the conferences?
Investors can participate in Q&A sessions throughout the conferences and are able to submit questions beforehand to the management team.
What is the purpose of the Hemopurifier?
The Hemopurifier is designed specifically to target and eliminate life-threatening viruses and exosomes, offering support for patients battling cancer and severe infections.
